Clinigen Group plc Appointment of COO
04 January 2021 - 6:00PM
RNS Non-Regulatory
TIDMCLIN
Clinigen Group plc
04 January 2021
4 January 2021
Clinigen Group plc
Clinigen appoints Sam Herbert as Chief Operating Officer
Clinigen Group plc ('Clinigen' or the 'Group'), the global
pharmaceutical and services company, has appointed Sam Herbert as
Chief Operating Officer. His appointment is effective immediately
and he will be based in the UK.
Sam is an experienced international healthcare pharmaceutical
executive with a background in driving growth and change in global
supply and distribution businesses. He brings a track record of
leading businesses through commercial and service expansion which
will support Clinigen's growth plans as it continues to realise its
vision of becoming the global leader in access to medicines.
Before joining Clinigen, he spent seven years at World Courier,
a leading provider of specialty logistics and distribution services
to the pharmaceutical, biotech and healthcare community. He joined
as Vice President, Strategy, rising to become Chief Operating
Officer and finally, President. His role developed from leading on
the implementation of a transformation strategy following World
Couriers' acquisition by AmerisourceBergen in 2012 to ultimately
driving the overall company's performance as President, responsible
for >3,000 people across 56 countries. Prior to World Courier,
Sam worked for Oliver Wyman, a leading international management
consulting firm and built their Health & Life Sciences practice
in Europe.
Sam has an AB in Economics (cum laude) from Harvard College and
is a Non-Executive Director of 7Bridges, an innovative AI-driven
logistics platform company.
Shaun Chilton, Group Chief Executive Officer, Clinigen,
said:
"We have been building out Clinigen's global platform in order
to fully realise our vision of being the Trusted Global Leader in
Access to Medicines. Now, more than ever, Clinigen has an important
role to play in getting essential medicines across the world to the
patients that need them. In adding the Chief Operating Officer role
and with it, someone of Sam's calibre and experience into the
management team, this gives us more bandwidth and will
significantly help us focus on executing our growth strategy and
the significant number of opportunities the platform is
creating."
Sam Herbert, new Chief Operating Officer, said:
"I am excited about joining Clinigen at such an important time
in its development as a company. It is clear that the challenge to
enable access to increasingly complex medicines across the world
has increased exponentially. I am looking forward to joining the
team at Clinigen and using my experience to help the Group meet the
needs of its pharma clients and HCP customers alike, in order to
benefit patients."
Ends -
Contact details
Clinigen Group plc Tel: +44 (0) 1283 495010
Shaun Chilton, Chief Executive Officer
Nick Keher, Group Chief Financial Officer
Numis Securities Limited - Nominated Adviser Tel: +44 (0) 20 7260
& Joint Broker 1000
James Black / Garry Levin / Freddie Barnfield
Tel: +44 (0) 20 7653
RBC Capital Markets - Joint Broker 4000
Marcus Jackson / Elliot Thomas
Instinctif Partners Tel: +44 (0) 20 7457
2020
Melanie Toyne-Sewell / Phillip Marriage Email: clinigen@instinctif.com
Notes to Editors
About Clinigen Group
Clinigen Group plc (AIM: CLIN) is a global pharmaceutical and
services company with a unique combination of businesses focused on
providing ethical access to medicines. Its mission is to deliver
the right medicine to the right patient at the right time through
three areas of global medicine supply; clinical trial, unlicensed
and licensed medicines. The Group has sites in North America,
Europe, Africa and Asia Pacific.
Clinigen now has over 1,100 employees across five continents in
14 countries, with supply and distribution hubs and operational
centres of excellence in key long-term growth regions. The Group
works with 22 of the top 25 pharmaceutical companies; interacting
with over 15,000 registered users across over 100 countries,
shipping approximately 6.4 million units in the year.
For more information on Clinigen, please visit
www.clinigengroup.com
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRADBGDBIUGDGBX
(END) Dow Jones Newswires
January 04, 2021 02:00 ET (07:00 GMT)
Clinigen (LSE:CLIN)
Historical Stock Chart
From Apr 2024 to May 2024
Clinigen (LSE:CLIN)
Historical Stock Chart
From May 2023 to May 2024